Takeda Pharmaceutical Co. $TAK Shares Bought by Gold Investment Management Ltd.

Gold Investment Management Ltd. grew its position in Takeda Pharmaceutical Co. (NYSE:TAK) by 2.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 100,048 shares of the company’s stock after buying an additional 2,490 shares during the quarter. Gold Investment Management Ltd.’s holdings in Takeda Pharmaceutical were worth $1,540,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Takeda Pharmaceutical by 22.6% in the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock valued at $105,000 after purchasing an additional 1,296 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Takeda Pharmaceutical by 5.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock worth $319,000 after buying an additional 1,098 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in Takeda Pharmaceutical by 29.2% during the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after buying an additional 1,045 shares during the last quarter. Vontobel Holding Ltd. purchased a new stake in Takeda Pharmaceutical during the 1st quarter worth about $262,000. Finally, Park Avenue Securities LLC lifted its holdings in Takeda Pharmaceutical by 15.1% during the 1st quarter. Park Avenue Securities LLC now owns 31,828 shares of the company’s stock worth $473,000 after buying an additional 4,177 shares during the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Zacks Research downgraded Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Takeda Pharmaceutical currently has an average rating of “Hold”.

Takeda Pharmaceutical Stock Up 0.8%

Takeda Pharmaceutical stock opened at $14.76 on Thursday. Takeda Pharmaceutical Co. has a fifty-two week low of $12.80 and a fifty-two week high of $15.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. The company has a market capitalization of $46.95 billion, a P/E ratio of 49.18 and a beta of 0.21. The stock has a 50-day simple moving average of $14.84 and a 200-day simple moving average of $14.83.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.